DGAP-News

Vita 34 AG Publishes Financial Figures for the First Half-Year 2014

DGAP-News: Vita 34 AG / Key word(s): Half Year Results
Vita 34 AG Publishes Financial Figures for the First Half-Year 2014

24.07.2014 / 07:35

---------------------------------------------------------------------

Vita 34 AG Publishes Financial Figures for the First Half-Year 2014

- Period result increases 67 percent to EUR 114k

- EBITDA of EUR 0.8 million nearly at the prior year's level; EBITDA
margin 13.4 percent

- Market introduction of "VitaPlusCord" [VitaPlusNabelschnur] additional
product advanced further

Leipzig, 24 July 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the storage
of stem cells from umbilical cord blood and tissue, and a specialist in
cryo-preservation, published its financial figures for the first six months
of fiscal year 2014 today. Vita 34 was able to continue the successful
development of the company, and reported a 67 percent increase in its
period result as compared with the prior year.

In the reporting period Vita 34 continued with the introduction of its
"VitaPlusCord" [VitaPlusNabelschnur] additional product, and was able to
obtain numerous official permits in Germany by the end of the reporting
period. The new offer was met with growing demand in the international
markets such as Austria, Switzerland, Slovenia, Romania, Bulgaria,
Macedonia and Croatia, as well. In addition, Spanish subsidiary Secuvita
S.L. has prepared the storage of umbilical cord tissue in the reporting
period.

At the same time it has not yet been possible to provide the new offering
for the cryo-preservation of umbilical cord tissue comprehensively
throughout Germany, since the official permitting process is proving more
time consuming than expected. The number of storages of umbilical cord
blood and tissue in the reporting period was 3,395 new storages (first
half-year 2013: 3,570 new storages). Correspondingly, Vita 34 AG earned
operating income in the amount of EUR 6.6 million in the first half-year
2014 (prior year's period: EUR 6.9 million). In comparison with the prior
year revenues decreased by 6.3 percent from EUR 6.5 million to EUR 6.1
million. According to business segment in the first six months of 2014 some
EUR 5.8 million in revenue was attributable to the Stem Cell Banking
segment (first half-year 2013: EUR 6.2 million). Revenues in the
Biotechnology segment of some EUR 0.3 million were at the level of the same
period the prior year (first half-year 2013: EUR 0.3 million).

The development of Vita 34 was shaped successfully with the cost reduction